G-protein-coupled receptor kinase 2 and hypertension: Molecular insights and pathophysiological mechanisms

High Blood Pressure and Cardiovascular Prevention

Volumn 20, Issue 1, 2013, Pages 5-12

  Santulli, Gaetano ^a,b   Trimarco, Bruno ^a   Iaccarino, Guido ^c,d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Columbia University Medical Center ^*  (United States)

^c IRCCS MULTIMEDICA   (Italy)

^d UNIVERSITY OF SALERNO   (Italy)

Author keywords

Adrenergic receptors; Endothelium; GRK; Hypertension; Vascular tone

Indexed keywords

ACETYLCHOLINE; ADENOSINE; ADRENALIN; ADRENOMEDULLIN; AMYLIN; ANGIOTENSIN II; APELIN; BRADYKININ; CALCITONIN GENE RELATED PEPTIDE; DOPAMINE; ENDOTHELIN; ENDOTHELIN 1; G PROTEIN COUPLED RECEPTOR KINASE; G PROTEIN COUPLED RECEPTOR KINASE 2; GHRELIN; HISTAMINE; LEUKOTRIENE B4; LEUKOTRIENE D4; MOTILIN; NEUROKININ A; NEUROPEPTIDE Y; NOCICEPTIN; NORADRENALIN; NUCLEOTIDE; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; THROMBIN; THROMBOCYTE ACTIVATING FACTOR; VASOPRESSIN;

ADRENERGIC SYSTEM; ARTERIAL PRESSURE; ATHEROSCLEROSIS; BLOOD VESSEL TONE; CARDIOVASCULAR RISK; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CEREBROVASCULAR DISEASE; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MATERNAL HYPERTENSION; NONHUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; ARTERIAL PRESSURE; ENDOTHELIUM, VASCULAR; G-PROTEIN-COUPLED RECEPTOR KINASE 2; HUMANS; HYPERTENSION; RECEPTORS, ADRENERGIC; SIGNAL TRANSDUCTION; UP-REGULATION; VASODILATION;

EID: 84879391693     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.1007/s40292-013-0001-8     Document Type: Review

References (94)

1. Santulli G. Coronary heart disease risk factors and mortality. JAMA. 2012;307(11):1137.
2. Trimarco B, Ricciardelli B, Cuocolo A, Volpe M, De Luca N, Mele AF, et al. Effects of coronary occlusion on arterial baroreflex control of heart rate and vascular resistance. Am J Physiol. 1987;252(4 Pt 2):H749-59.
3. Savoia C, Touyz RM, Volpe M, Schiffrin EL. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension. 2007;49(2):341-6.
4. Iaccarino G, Ciccarelli M, Sorriento D, Cipolletta E, Cerullo V, Iovino GL, et al. AKT participates in endothelial dysfunction in hypertension. Circulation. 2004;109(21):2587-93.
5. Tocchetti CG, Stanley BA, Murray CI, Sivakumaran V, Donzelli S, Mancardi D, et al. Playing with cardiac "redox switches": the "HNO way" to modulate cardiac function. Antioxid Redox Signal. 2011;14(9):1687-98
6. Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S, et al. CaMK4 gene deletion induces hypertension. J Am Heart Assoc. 2012;1:e001081.
7. Lymperopoulos A. Ischemic emergency? Endothelial cells have their own 'adrenaline shot' at hand. Hypertension. 2012;60(1):12-4.
8. Iaccarino G, Ciccarelli M, Sorriento D, Galasso G, Campanile A, Santulli G, et al. Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res. 2005;97(11):1182-9.
9. Sorriento D, Santulli G, Del Giudice C, Anastasio A, Trimarco B, Iaccarino G. Endothelial cells are able to synthesize and release catecholamines both in vitro and in vivo. Cardiovasc Res. 2012;93:S61-75.
10. Santulli G, Ciccarelli M, Palumbo G, Campanile A, Galasso G, Ziaco B, et al. In vivo properties of the proangiogenic peptide QK. J Transl Med. 2009;7:41.
11. Ciccarelli M, Santulli G, Campanile A, Galasso G, Cervero P, Altobelli GG, et al. Endothelial alpha1-adrenoceptors regulate neo-angiogenesis. Br J Pharmacol. 2008;153(5):936-46.
12. Sorriento D, Santulli G, Del Giudice C, Anastasio A, Trimarco B, Iaccarino G. Endothelial cells are able to synthesize and release catecholamines both in vitro and in vivo. Hypertension. 2012;60(1):129-36.
13. Izzo R, Cipolletta E, Ciccarelli M, Campanile A, Santulli G, Palumbo G, et al. Enhanced GRK2 expression and desensitization of betaAR vasodilatation in hypertensive patients. Clin Transl Sci. 2008;1(3):215-20.
14. Stein CM, Nelson R, Deegan R, He H, Wood M, Wood AJ. Forearm beta adrenergic receptor-mediated vasodilation is impaired, without alteration of forearm norepinephrine spillover, in borderline hypertension. J Clin Invest. 1995;96(1):579-85.
15. Khalaila JM, Elami A, Caraco Y. Interaction between beta2 adrenergic receptor polymorphisms determines the extent of isoproterenol-induced vasodilatation ex vivo. Pharmacogenet Genomics. 2007;17(10):803-11.
16. Cockcroft JR, Gazis AG, Cross DJ, Wheatley A, Dewar J, Hall IP, et al. Beta(2)-adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension. 2000;36(3):371-5.
17. Hindorff LA, Heckbert SR, Psaty BM, Lumley T, Siscovick DS, Herrington DM, et al. Beta(2)-adrenergic receptor polymorphisms and determinants of cardiovascular risk: the Cardiovascular Health Study. Am J Hypertens. 2005;18(3):392-7.
18. Barbato E, Berger A, Delrue L, Van Durme F, Manoharan G, Boussy T, et al. GLU-27 variant of beta2-adrenergic receptor polymorphisms is an independent risk factor for coronary atherosclerotic disease. Atherosclerosis. 2007;194(2):e80-6.
19. Drake MT, Shenoy SK, Lefkowitz RJ. Trafficking of G protein-coupled receptors. Circ Res. 2006;99(6):570-82.
20. Lymperopoulos A, Bathgate A. Pharmacogenomics of the heptahelical receptor regulators G-protein-coupled receptor kinases and arrestins: the known and the unknown. Pharmacogenomics. 2012;13(3):323-41.
21. Feldman RD, Limbird LE, Nadeau J, Robertson D, Wood AJ. Leukocyte beta-receptor alterations in hypertensive subjects. J Clin Invest. 1984;73(3):648-53.
22. Lefkowitz RJ, Cotecchia S, Kjelsberg MA, Pitcher J, Koch WJ, Inglese J, et al. Adrenergic receptors: recent insights into their mechanism of activation and desensitization. Adv Second Messenger Phosphoprot Res. 1993;28:1-9.
23. Zeiders JL, Seidler FJ, Iaccarino G, Koch WJ, Slotkin TA. Ontogeny of cardiac beta-adrenoceptor desensitization mechanisms: agonist treatment enhances receptor/G-protein transduction rather than eliciting uncoupling. J Mol Cell Cardiol. 1999;31(2):413-23.
24. Iaccarino G, Lefkowitz RJ, Koch WJ. Myocardial G protein-coupled receptor kinases: implications for heart failure therapy. Proc Assoc Am Phys. 1999;111(5):399-405.
25. Iaccarino G, Keys JR, Rapacciuolo A, Shotwell KF, Lefkowitz RJ, Rockman HA, et al. Regulation of myocardial betaARK1 expression in catecholamine-induced cardiac hypertrophy in transgenic mice overexpressing alpha1B-adrenergic receptors. J Am Coll Cardiol. 2001;38(2):534-40.
26. Harris DM, Cohn HI, Pesant S, Eckhart AD. GPCR signalling in hypertension: role of GRKs. Clin Sci (Lond). 2008;115(3):79-89.
27. Iaccarino G, Campanile A, Santulli G, Zuppieri F, Koch WJ. G protein-coupled receptor kinases and hypertension: a review of disease mechanisms. High Blood Press Cardiovasc Prev. 2006;13(4):151-8.
28. Arraes SM, Freitas MS, da Silva SV, de Paula Neto HA, Alves-Filho JC, Auxiliadora Martins M, et al. Impaired neutrophil chemotaxis in sepsis associates with GRK expression and inhibition of actin assembly and tyrosine phosphorylation. Blood. 2006;108(9):2906-13.
29. Yoshida N, Haga K, Haga T. Identification of sites of phosphorylation by G-protein-coupled receptor kinase 2 in beta-tubulin. Eur J Biochem. 2003;270(6):1154-63.
30. Liu X, Ma B, Malik AB, Tang H, Yang T, Sun B, et al. Bidirectional regulation of neutrophil migration by mitogen-activated protein kinases. Nat Immunol. 2012;13(5):457-64.
31. Sakamoto M, Arawaka S, Hara S, Sato H, Cui C, Machiya Y, et al. Contribution of endogenous G-protein-coupled receptor kinases to Ser129 phosphorylation of alpha-synuclein in HEK293 cells. Biochem Biophys Res Commun. 2009;384(3):378-82.
32. Kahsai AW, Zhu S, Fenteany G. G protein-coupled receptor kinase 2 activates radixin, regulating membrane protrusion and motility in epithelial cells. Biochim Biophys Acta. 2010;1803(2):300-10.
33. Cant SH, Pitcher JA. G protein-coupled receptor kinase 2-mediated phosphorylation of ezrin is required for G protein-coupled receptor-dependent reorganization of the actin cytoskeleton. Mol Biol Cell. 2005;16(7):3088-99.
34. Tesmer VM, Kawano T, Shankaranarayanan A, Kozasa T, Tesmer JJ. Snapshot of activated G proteins at the membrane: the Galphaq-GRK2-Gbetagamma complex. Science. 2005;310(5754):1686-90.
35. Lodowski DT, Pitcher JA, Capel WD, Lefkowitz RJ, Tesmer JJ. Keeping G proteins at bay: a complex between G protein-coupled receptor kinase 2 and Gbetagamma. Science. 2003;300(5623):1256-62.
36. Jaber M, Koch WJ, Rockman H, Smith B, Bond RA, Sulik KK, et al. Essential role of beta-adrenergic receptor kinase 1 in cardiac development and function. Proc Natl Acad Sci USA. 1996;93(23):12974-9.
37. Gainetdinov RR, Bohn LM, Sotnikova TD, Cyr M, Laakso A, Macrae AD, et al. Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron. 2003;38(2):291-303.
38. Lyubarsky AL, Chen C, Simon MI, Pugh EN Jr. Mice lacking G-protein receptor kinase 1 have profoundly slowed recovery of cone-driven retinal responses. J Neurosci. 2000;20(6):2209-17.
39. Peppel K, Boekhoff I, McDonald P, Breer H, Caron MG, Lefkowitz RJ. G protein-coupled receptor kinase 3 (GRK3) gene disruption leads to loss of odorant receptor desensitization. J Biol Chem. 1997;272(41):25425-8.
40. Walker JK, Gainetdinov RR, Feldman DS, McFawn PK, Caron MG, Lefkowitz RJ, et al. G protein-coupled receptor kinase 5 regulates airway responses induced by muscarinic receptor activation. Am J Physiol Lung Cell Mol Physiol. 2004;286(2):L312-9.
41. Chen Y, Sasai N, Ma G, Yue T, Jia J, Briscoe J, et al. Sonic Hedgehog dependent phosphorylation by CK1alpha and GRK2 is required for ciliary accumulation and activation of smoothened. PLoS Biol. 2011;9(6):e1001083.
42. Fusco A, Santulli G, Sorriento D, Cipolletta E, Garbi C, Dorn GW 2nd, et al. Mitochondrial localization unveils a novel role for GRK2 in organelle biogenesis. Cell Signal. 2011;24(2):468-75.
43. Iaccarino G, Barbato E, Cipolletta E, De Amicis V, Margulies KB, Leosco D, et al. Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J. 2005;26(17):1752-8.
44. Iacovelli L, Franchetti R, Masini M, De Blasi A. GRK2 and beta-arrestin 1 as negative regulators of thyrotropin receptor-stimulated response. Mol Endocrinol. 1996;10(9):1138-46.
45. Ferrer-Alcon M, La Harpe R, Garcia-Sevilla JA. Decreased immunodensities of micro-opioid receptors, receptor kinases GRK 2/6 and beta-arrestin-2 in postmortem brains of opiate addicts. Brain Res Mol Brain Res. 2004;121(1-2):114-22.
46. Mak JC, Chuang TT, Harris CA, Barnes PJ. Increased expression of G protein-coupled receptor kinases in cystic fibrosis lung. Eur J Pharmacol. 2002;436(3):165-72.
47. Obrenovich ME, Morales LA, Cobb CJ, Shenk JC, Mendez GM, Fischbach K, et al. Insights into cerebrovascular complications and Alzheimer disease through the selective loss of GRK2 regulation. J Cell Mol Med. 2009;13(5):853-65.
48. Vroon A, Kavelaars A, Limmroth V, Lombardi MS, Goebel MU, Van Dam AM, et al. G protein-coupled receptor kinase 2 in multiple sclerosis and experimental autoimmune encephalomyelitis. J Immunol. 2005;174(7):4400-6.
49. Lombardi MS, Kavelaars A, Cobelens PM, Schmidt RE, Schedlowski M, Heijnen CJ. Adjuvant arthritis induces down-regulation of G protein-coupled receptor kinases in the immune system. J Immunol. 2001;166(3):1635-40.
50. King DW, Steinmetz R, Wagoner HA, Hannon TS, Chen LY, Eugster EA, et al. Differential expression of GRK isoforms in nonmalignant and malignant human granulosa cells. Endocrine. 2003;22(2):135-42.
51. Gros R, Benovic JL, Tan CM, Feldman RD. G-protein-coupled receptor kinase activity is increased in hypertension. J Clin Invest. 1997;99(9):2087-93.
52. Borkowski KR, Gros R, Schneider H. Vascular beta-adrenoceptor-mediated responses in hypertension and ageing in rats. J Auton Pharmacol. 1992;12(6):389-401.
53. Gros R, Chorazyczewski J, Meek MD, Benovic JL, Ferguson SS, Feldman RD. G-Protein-coupled receptor kinase activity in hypertension: increased vascular and lymphocyte G-protein receptor kinase-2 protein expression. Hypertension. 2000;35(1 Pt 1):38-42.
54. Eckhart AD, Ozaki T, Tevaearai H, Rockman HA, Koch WJ. Vascular-targeted overexpression of G protein-coupled receptor kinase-2 in transgenic mice attenuates beta-adrenergic receptor signaling and increases resting blood pressure. Mol Pharmacol. 2002;61(4):749-58.
55. Morris GE, Nelson CP, Brighton PJ, Standen NB, Challiss RA, Willets JM. Arrestins 2 and 3 differentially regulate ETA and P2Y2 receptor-mediated cell signaling and migration in arterial smooth muscle. Am J Physiol Cell Physiol. 2012;302(5):C723-34.
56. Erbel R, Lehmann N, Mohlenkamp S, Churzidse S, Bauer M, Kalsch H, et al. Subclinical coronary atherosclerosis predicts cardiovascular risk in different stages of hypertension: result of the Heinz Nixdorf Recall Study. Hypertension. 2012;59(1):44-53.
57. Liu S, Premont RT, Kontos CD, Zhu S, Rockey DC. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med. 2005;11(9):952-8.
58. Taguchi K, Kobayashi T, Matsumoto T, Kamata K. Dysfunction of endothelium-dependent relaxation to insulin via PKC-mediated GRK2/Akt activation in aortas of ob/ob mice. Am J Physiol Heart Circ Physiol. 2011;301(2):H571-83.
59. Leosco D, Iaccarino G, Cipolletta E, De Santis D, Pisani E, Trimarco V, et al. Exercise restores beta-adrenergic vasorelaxation in aged rat carotid arteries. Am J Physiol Heart Circ Physiol. 2003;285(1):H369-74.
60. Taguchi K, Matsumoto T, Kamata K, Kobayashi T. Inhibitor of G protein-coupled receptor kinase 2 normalizes vascular endothelial function in type 2 diabetic mice by improving beta-arrestin 2 translocation and ameliorating Akt/eNOS signal dysfunction. Endocrinology. 2012;153(7):2985-96.
61. Napolitano R, Campanile A, Sarno L, Anastasio A, Maruotti GM, Morlando M, et al. GRK2 levels in umbilical arteries of pregnancies complicated by gestational hypertension and preeclampsia. Am J Hypertens. 2012;25(3):366-71.
62. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649-58.
63. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012;125(7):911-9.
64. Santulli G, Lombardi A, Sorriento D, Anastasio A, Del Giudice C, Formisano P, et al. Age-related impairment in insulin release: the essential role of beta(2)-adrenergic receptor. Diabetes. 2012;61(3):692-701.
65. De Boer MP, Meijer RI, Wijnstok NJ, Jonk AM, Houben AJ, Stehouwer CD, et al. Microvascular dysfunction: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Microcirculation. 2012;19(1):5-18.
66. Usui I, Imamura T, Babendure JL, Satoh H, Lu JC, Hupfeld CJ, et al. G protein-coupled receptor kinase 2 mediates endothelin-1-induced insulin resistance via the inhibition of both Galphaq/11 and insulin receptor substrate-1 pathways in 3T3-L1 adipocytes. Mol Endocrinol. 2005;19(11):2760-8.
67. Ciccarelli M, Chuprun JK, Rengo G, Gao E, Wei Z, Peroutka RJ, et al. G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. Circulation. 2011;123(18):1953-62.
68. Cipolletta E, Campanile A, Santulli G, Sanzari E, Leosco D, Campiglia P, et al. The G protein coupled receptor kinase 2 plays an essential role in beta-adrenergic receptor-induced insulin resistance. Cardiovasc Res. 2009;84(3):407-15.
69. Santulli G, Campanile A, Spinelli L, Assante di Panzillo E, Assante di Panzillo E, Ciccarelli M, Trimarco B, et al. G protein-coupled receptor kinase 2 in patients with acute myocardial infarction. Am J Cardiol. 2011;107(8):1125-30.
70. Feldman RD. Deactivation of vasodilator responses by GRK2 overexpression: a mechanism or the mechanism for hypertension? Mol Pharmacol. 2002;61(4):707-9.
71. Zhu X, Brown B, Li A, Mears AJ, Swaroop A, Craft CM. GRK1-dependent phosphorylation of S and M opsins and their binding to cone arrestin during cone phototransduction in the mouse retina. J Neurosci. 2003;23(14):6152-60.
72. Zhao X, Yokoyama K, Whitten ME, Huang J, Gelb MH, Palczewski K. A novel form of rhodopsin kinase from chicken retina and pineal gland. FEBS Lett. 1999;454(1-2):115-21.
73. Arnon TI, Xu Y, Lo C, Pham T, An J, Coughlin S, et al. GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood. Science. 2011;333(6051):1898-903.
74. Shahid G, Hussain T. GRK2 negatively regulates glycogen synthesis in mouse liver FL83B cells. J Biol Chem. 2007;282(28):20612-20.
75. Lymperopoulos A, Rengo G, Gao E, Ebert SN, Dorn GW 2nd, Koch WJ. Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. J Biol Chem. 2010;285(21):16378-86.
76. Taneja M, Salim S, Saha K, Happe HK, Qutna N, Petty F, et al. Differential effects of inescapable stress on locus coeruleus GRK3, alpha2-adrenoceptor and CRF1 receptor levels in learned helpless and non-helpless rats: a potential link to stress resilience. Behav Brain Res. 2011;221(1):25-33.
77. von Lueder TG, Gravning J, How OJ, Vinge LE, Ahmed MS, Krobert KA, et al. Cardiomyocyte-restricted inhibition of G protein-coupled receptor kinase-3 (GRK3) attenuates cardiac dysfunction after chronic pressure overload. Am J Physiol Heart Circ Physiol. 2012;303(1):H66-74.
78. Harris RC. Abnormalities in renal dopamine signaling and hypertension: the role of GRK4. Curr Opin Nephrol Hypertens. 2012;21(1):61-5.
79. Liu C, Xi B. Pooled analyses of the associations of polymorphisms in the GRK4 and EMILIN1 genes with hypertension risk. Int J Med Sci. 2012;9(4):274-9.
80. Sorriento D, Santulli G, Fusco A, Anastasio A, Trimarco B, Iaccarino G. Intracardiac injection of AdGRK5-NT reduces left ventricular hypertrophy by inhibiting NF-kappaB-dependent hypertrophic gene expression. Hypertension. 2010;56(4):696-704.
81. Cheng S, Li L, He S, Liu J, Sun Y, He M, et al. GRK5 deficiency accelerates {beta}-amyloid accumulation in Tg2576 mice via impaired cholinergic activity. J Biol Chem. 2010;285(53):41541-8.
82. Islam KN, Koch WJ. Involvement of nuclear factor kappaB (NF-kappaB) signaling pathway in regulation of cardiac G protein-coupled receptor kinase 5 (GRK5) expression. J Biol Chem. 2012;287(16):12771-8.
83. Eijkelkamp N, Heijnen CJ, Carbajal AG, Willemen HL, Wang H, Minett MS, et al. GRK6 acts as a critical regulator of cytokine-induced hyperalgesia by promoting PI3kinase- and inhibiting p38-signaling. Mol Med. 2012;18(1):556-64.
84. Tiedemann RE, Zhu YX, Schmidt J, Yin H, Shi CX, Que Q, et al. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood. 2010;115(8):1594-604.
85. Ahmed MR, Berthet A, Bychkov E, Porras G, Li Q, Bioulac BH, et al. Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Sci Transl Med. 2010;2(28):28ra.
86. Chen CK, Zhang K, Church-Kopish J, Huang W, Zhang H, Chen YJ, et al. Characterization of human GRK7 as a potential cone opsin kinase. Mol Vis. 2001;7:305-13.
87. Osawa S, Jo R, Weiss ER. Phosphorylation of GRK7 by PKA in cone photoreceptor cells is regulated by light. J Neurochem. 2008;107(5):1314-24.
88. Eckhart AD, Duncan SJ, Penn RB, Benovic JL, Lefkowitz RJ, Koch WJ. Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. Circ Res. 2000;86(1):43-50.
89. Cohn HI, Harris DM, Pesant S, Pfeiffer M, Zhou RH, Koch WJ, et al. Inhibition of vascular smooth muscle G protein-coupled receptor kinase 2 enhances alpha1D-adrenergic receptor constriction. Am J Physiol Heart Circ Physiol. 2008;295(4):H1695-704.
90. Koch WJ, Rockman HA, Samama P, Hamilton RA, Bond RA, Milano CA, et al. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science. 1995;268(5215):1350-3.
91. Rockman HA, Choi DJ, Akhter SA, Jaber M, Giros B, Lefkowitz RJ, et al. Control of myocardial contractile function by the level of beta-adrenergic receptor kinase 1 in gene-targeted mice. J Biol Chem. 1998;273(29):18180-4.
92. 2+ handling phenotype resistant to adverse alterations and remodeling after myocardial infarction. Circulation. 2012;125(17):2108-18.
93. Rockman HA, Choi DJ, Rahman NU, Akhter SA, Lefkowitz RJ, Koch WJ. Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc Natl Acad Sci USA. 1996;93(18):9954-9.
94. Spurney RF, Flannery PJ, Garner SC, Athirakul K, Liu S, Guilak F, et al. Anabolic effects of a G protein-coupled receptor kinase inhibitor expressed in osteoblasts. J Clin Invest. 2002;109(10):1361-71.